Aquilina J, Maplethorpe R, Ellis P, Harrington K
The Homerton Hospital NHS Trust & St Bartholomew's and the Royal London School of Medicine and Dentistry, Queen Mary & Westfield College, London, UK.
Placenta. 2000 Jul-Aug;21(5-6):487-92. doi: 10.1053/plac.2000.0540.
We aimed to investigate the relationship between inhibin-A and human chorionic gonadotrophin (hCG) concentrations in the second trimester in the same cohort of women and compare their screening efficiency for the subsequent development of pre-eclampsia. The main outcome measures were pre-eclampsia and pre-eclampsia requiring delivery before 37 weeks.We carried out a retrospective examination of inhibin-A and free beta-hCG levels taken between 15 and 19 weeks of gestation, from 685 women. The values were corrected for weight and gestation and presented as multiples of the median (MoM). Receiver operator characteristic (ROC) curves for the prediction of pre-eclampsia and pre-eclampsia requiring delivery before 37 weeks were created for both analytes alone and in combination. Based on this data the sensitivities for the prediction of pre-eclampsia using inhibin-A and hCG, alone and in combination were examined for a specificity of 90 per cent.Thirty-five (5.5 per cent) women developed pre-eclampsia, of whom 15 (2.7 per cent) required delivery before term as a result of pre-eclampsia. There was no correlation between inhibin-A and hCG for the whole population (r=0.08) but there was a significant correlation for women who subsequently developed pre-eclampsia (r=0.648) or preterm pre-eclampsia (r=0.84). For a specificity of 90 per cent the sensitivity using inhibin-A was significantly better than for hCG (48.6 per cent versus 31.4 per cent, P< 0.05). The results were similar for preterm pre-eclampsia (P< 0.05). The addition of hCG data to inhibin-A data did not improve the sensitivity for pre-eclampsia compared to inhibin-A alone (42.9 per cent versus 48.6 per cent, P< 0.20).Inhibin-A is a more sensitive marker for the subsequent development of pre-eclampsia than hCG. Addition of hCG data to inhibin-A did not improve the screening efficacy for pre-eclampsia suggesting that inhibin-A and hCG are markers of the same underlying pathological process.
我们旨在研究同一组孕妇孕中期抑制素A与人类绒毛膜促性腺激素(hCG)浓度之间的关系,并比较它们对先兆子痫后续发展的筛查效率。主要观察指标为先兆子痫和孕37周前因先兆子痫而需要分娩的情况。我们对685名女性在妊娠15至19周期间采集的抑制素A和游离β-hCG水平进行了回顾性检查。这些值根据体重和孕周进行了校正,并以中位数倍数(MoM)表示。分别针对两种分析物单独及联合使用时,绘制了预测先兆子痫和孕37周前因先兆子痫而需要分娩的受试者工作特征(ROC)曲线。基于这些数据,在特异性为90%的情况下,对单独使用抑制素A和hCG以及联合使用它们预测先兆子痫的敏感性进行了检验。35名(5.5%)女性发生了先兆子痫,其中15名(2.7%)因先兆子痫在足月前需要分娩。在整个人群中,抑制素A与hCG之间无相关性(r = 0.08),但在随后发生先兆子痫的女性中存在显著相关性(r = 0.648),在早产先兆子痫女性中也存在显著相关性(r = 0.84)。在特异性为90%时,使用抑制素A的敏感性显著优于hCG(48.6%对31.4%,P < 0.05)。早产先兆子痫的结果相似(P < 0.05)。与单独使用抑制素A相比,将hCG数据添加到抑制素A数据中并未提高先兆子痫的敏感性(42.9%对48.6%,P < 0.20)。抑制素A是先兆子痫后续发展比hCG更敏感的标志物。将hCG数据添加到抑制素A中并未提高先兆子痫的筛查效率,这表明抑制素A和hCG是同一潜在病理过程的标志物。